What is ProLynx?
ProLynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The company's proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics. This innovative approach targets a critical unmet need in chronic disease management, aiming to provide patients with more convenient and effective therapeutic options.
How much funding has ProLynx raised?
ProLynx has raised a total of $70.4M across 3 funding rounds:
Debt
$150K
Debt
$207K
Series A
$70M
Debt (2020): $150K with participation from PPP
Debt (2021): $207K led by PPP
Series A (2025): $70M supported by OrbiMed, Monograph Capital, and 5AM Ventures
Key Investors in ProLynx
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Monograph Capital
Monograph Capital is focused on finding and funding innovative life sciences companies to help translate promising science into life-changing treatments for patients globally. The firm operates with a transatlantic team that sources leading scientific innovations and supports the development of strong companies.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
What's next for ProLynx?
With this major strategic investment, ProLynx is poised to accelerate the development and potential commercialization of its novel drug candidates. The company's focus on extending the half-life of medications is a key differentiator, promising to reduce dosing frequency and improve patient adherence. This capital infusion will likely fuel further research and development, clinical trials, and strategic partnerships, positioning ProLynx for significant growth in the competitive biotechnology landscape. The company's trajectory suggests a move towards scaling operations and solidifying its market presence in metabolic health.
See full ProLynx company page
